TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19696778

Group type: EXPERIMENTAL
Intervention: Azelnidipine (8-16 mg day(‐1))
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trichlormethiazide (1-2 mg day(‐1))
Number of subjects: 29
Study: 17199066

Group type: EXPERIMENTAL
Intervention: Multisource feedback intervention (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard feedback only (Control group, n = 18)
Number of subjects: 36
Study: 14994318

Group type: EXPERIMENTAL
Intervention: Combined extract of Ginkgo biloba (120 mg) and Bacopa monniera (300 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 11474331

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 9738713

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 60
Study: 9817192

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Nitrendipine (10 mg twice or three times daily)
Number of subjects: 488
Study: 2501265

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 41

Group type: COMPARATOR
Intervention: Minocycline
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Doxycycline and Minocycline
Number of subjects: 41
Study: 765388

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30717671

Group type: EXPERIMENTAL
Intervention: Participants in the ORISCAV-LUX2 study (660 subjects)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Non-participants (549 subjects)
Number of subjects: 1558
Study: 27647855

Group type: EXPERIMENTAL
Intervention: TGF-b1mAb (2 mg monthly for 12 months)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: TGF-b1mAb (10 mg monthly for 12 months)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: TGF-b1mAb (50 mg monthly for 12 months)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 25406305

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study: 23913386

Group type: EXPERIMENTAL
Intervention: 80 mg/day telmisartan
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (during the 2-week run-in period)
Number of subjects: 148
Study: 21306709

Group type: EXPERIMENTAL
Intervention: Epidural analgesia combined with dexamethasone 0.2mg/mL (group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural analgesia alone using bupivacaine 0.125% and fentanyl 1 μg/mL (group I)
Number of subjects: 60
Study: 19254612

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surface hip arthroplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 17091415

Group type: EXPERIMENTAL
Intervention: Sonographic cervical length measurement
Number of subjects: 282

Group type: COMPARATOR
Intervention: Clinical digital examination (Bishop score)
Number of subjects: 282
Study: 15577591

Group type: EXPERIMENTAL
Intervention: Single intradermal injection of 99mTc nanocolloidal albumin (Nanocoll)
Number of subjects: 142
Study: 11421501

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 600 mg effervescent tablets, once a day for 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9200056

Group type: EXPERIMENTAL
Intervention: Intervention group offered screening; specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving usual medical care; specific details on dosage and duration not available.
Number of subjects: 0
Study: 8305994

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate antihypertensive drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study: 3828550

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) of 30 mmHg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) of 40 mmHg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) of 50 mmHg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 10
Study: 29793527

Group type: EXPERIMENTAL
Intervention: Preoperative education seminar
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 244
Study: 27479888

Group type: EXPERIMENTAL
Intervention: HCVAD plus ponatinib
Number of subjects: 110

Group type: COMPARATOR
Intervention: HCVAD plus dasatinib
Number of subjects: 110
Study: 24599482

Group type: EXPERIMENTAL
Intervention: Safe Dates program
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1690
Study: 22525650

Group type: EXPERIMENTAL
Intervention: CHO+PRO 2:1 ratio
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CHO+PRO 3:1 ratio
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CHO+PRO 4:1 ratio
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 28
Study: 19435644

Group type: EXPERIMENTAL
Intervention: 12-month supervised exercise program (TPAD-IC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal medical therapy (CPAD-IC)
Number of subjects: 21
Study: 17264145

Group type: EXPERIMENTAL
Intervention: Salbutamol (Sal; 4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 12
Study: 14760188

Group type: EXPERIMENTAL
Intervention: Enoxaparin and GP IIb/IIIa inhibitors during PCI
Number of subjects: 49

Group type: COMPARATOR
Intervention: Historical references utilizing unfractionated heparin
Number of subjects: 49
Study: 11454883

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg daily
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily
Number of subjects: 602

Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg qid
Number of subjects: 602
Study: 9743505

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol with vaginal micronized progesterone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Estradiol alone and combined with progesterone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Estradiol therapy (with and without progesterone)
Number of subjects: 17
Study: 7920316

Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Allogeneic BMT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 3291084

Group type: EXPERIMENTAL
Intervention: Serum cathodic trypsin-like immunoreactivity
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pancreatic lipase
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pancreatic isoamylase
Number of subjects: 105
Study: 7037037

Group type: EXPERIMENTAL
Intervention: Etretinate (75 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 28
Study: 31650412

Group type: EXPERIMENTAL
Intervention: SMART‐3RP intervention (8-session weekly group intervention delivered via videoconferencing)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait-list control group (WC)
Number of subjects: 53
Study: 30308127

Group type: EXPERIMENTAL
Intervention: 30 g of milled flaxseed daily for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (flaxseed and placebo)
Number of subjects: 0
Study: 28115461

Group type: EXPERIMENTAL
Intervention: Health questionnaire
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Presence of FH
Number of subjects: 775
Study: 25727933

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Skin stapling
Number of subjects: 1264
Study: 24706842

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 3-month regimens containing rifampicin or rifapentine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo or alternative regimen
Number of subjects: 3
Study: 22592094

Group type: COMPARATOR
Intervention: RBV 800 mg/day
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: RBV 1000/1200 mg/day
Number of subjects: 400
Study: 23098286

Group type: EXPERIMENTAL
Intervention: Disease management-health promotion nurse intervention
Number of subjects: 570

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570
Study: 17468681

Group type: EXPERIMENTAL
Intervention: 12‐Item Short Form Health Survey (SF‐12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of SF‐12 and Q‐LES‐Q
Number of subjects: 0
Study: 14697462

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20, 40, and 80 mg/day
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 196

Group type: COMPARATOR
Intervention: Fluvastatin, Pravastatin, Lovastatin, Simvastatin
Number of subjects: 196
Study: 11995751

Group type: EXPERIMENTAL
Intervention: Observational studies and randomised clinical trials
Number of subjects: 0
Study: 9649045

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 264
Study: 7984617

Group type: EXPERIMENTAL
Intervention: Thymogen in multi‐modality treatment
Number of subjects: 33
Study: 2656603

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 50
Study: 1065802

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg/day for 14 days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Indomethacin 210 mg/day for 14 days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pyrasanone 600 mg/day for 14 days
Number of subjects: 76
Study: 30452728

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 8182

Group type: EXPERIMENTAL
Intervention: Graphic health effects pictorial warnings
Number of subjects: 8182

Group type: EXPERIMENTAL
Intervention: Pictorial warnings with personal testimonials
Number of subjects: 8182
Study: 28492868

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25910537

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 7
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Daily filgrastim 5 µg/kg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 3
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim day 7
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Daily filgrastim
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Multiple myeloma patients
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim vs. filgrastim
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 134
Study: 22495454

Group type: EXPERIMENTAL
Intervention: Lung SBRT (Stereotactic body radiation therapy)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Use of fiducial markers
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Use of planar imaging
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Years of experience with lung SBRT
Number of subjects: 551
Study: 21717993

Group type: EXPERIMENTAL
Intervention: Cervical traction with 30% of body weight (Group C)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cervical traction with 10% of body weight (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cervical traction with 20% of body weight (Group B)
Number of subjects: 96
Study: 19851916

Group type: EXPERIMENTAL
Intervention: Online, individually tailored counseling report
Number of subjects: 2872

Group type: COMPARATOR
Intervention: Personalized but untailored generic report
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Tailored reports
Number of subjects: 2872

Group type: COMPARATOR
Intervention: Untailored reports
Number of subjects: 2872
Study: 17701771

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose hormone replacement therapy (HRT) - estradiol 1 mg/norethisterone acetate 0.5 mg daily
Number of subjects: 42
Study: 15521894

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11174186

Group type: EXPERIMENTAL
Intervention: Combined surgical and medical treatment (unilateral endoscopic sinus surgery after pretreatment with oral prednisolone for 10 days and local nasal budesonide bilaterally for 1 month)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Medical treatment (oral prednisolone and local nasal budesonide)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Surgery (unilateral endoscopic sinus surgery)
Number of subjects: 32
Study: 10405566

Group type: EXPERIMENTAL
Intervention: Patients with exacerbation of COPD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 40
Study: 7822198

Group type: EXPERIMENTAL
Intervention: Adjuvant group sports program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no sports program)
Number of subjects: 60
Study: 3127421

Group type: EXPERIMENTAL
Intervention: Humegon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pergonal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrodin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both preparations (Humegon and Pergonal)
Number of subjects: 0
Study: 30725265

Group type: EXPERIMENTAL
Intervention: Propofol sedation in patients with central-predominant hypoventilation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propofol sedation in patients with non-central-predominant hypoventilation
Number of subjects: 44
Study: 31287184

Group type: EXPERIMENTAL
Intervention: Therapeutic intervention using liquorice mouth wash
Number of subjects: 93

Group type: COMPARATOR
Intervention: Educational intervention (sign language and video modeling)
Number of subjects: 93
Study: 29166673

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1021
Study: 26152519

Group type: EXPERIMENTAL
Intervention: SMS text pre-notification of questionnaire delivery
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: E-mail reminder
Number of subjects: 418

Group type: COMPARATOR
Intervention: Postal reminder
Number of subjects: 418
Study: 23196938

Group type: EXPERIMENTAL
Intervention: ART-naive individuals
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Framingham Risk Score ≥ 6% per 10 years (N = 44)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Increasing age, height, weight, small LDL particles, black race
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Presence of carotid artery lesions
Number of subjects: 331
Study: 21587279

Group type: EXPERIMENTAL
Intervention: Polyunsaturated acid mixture treatment for 10 weeks
Number of subjects: 0
Study: 18203127

Group type: EXPERIMENTAL
Intervention: Variable selection using Rubin's rules (RR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stacked method combining multiply imputed data sets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete-case analysis
Number of subjects: 0
Study: 17716435

Group type: EXPERIMENTAL
Intervention: PermaNet nets
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Yorkool nets
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: A-Z nets
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventionally treated nets (using K-O Tab tablets)
Number of subjects: 200
Study: 12604518

Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxetil (100 mg tablet twice daily for 3 days)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (double-strength tablet [160/800 mg] twice daily for 3 days)
Number of subjects: 163
Study: 11123502

Group type: EXPERIMENTAL
Intervention: Vitamin E (91 mg d-alpha-tocopherol)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg slow-release vitamin C)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Combination of Vitamin E and C
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520

Group type: COMPARATOR
Intervention: Combination of Vitamin E and C vs. placebo
Number of subjects: 520
Study: 9197299

Group type: EXPERIMENTAL
Intervention: ORG 9487 at 0.75 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ORG 9487 at 1.5 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ORG 9487 at 2 mg/kg
Number of subjects: 30
Study: 8222176

Group type: EXPERIMENTAL
Intervention: Warm retrograde cardioplegia (group 2)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (group 1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cold retrograde blood cardioplegia (group 3)
Number of subjects: 163
Study: 3082774

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30220622

Group type: EXPERIMENTAL
Intervention: ABVD or AVD
Number of subjects: 67

Group type: COMPARATOR
Intervention: BEACOPP-14 or escalated BEACOPP
Number of subjects: 67
Study: 27434092

Group type: EXPERIMENTAL
Intervention: Diet enriched with arabinoxylan and resistant starch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-fibre Western-style diet
Number of subjects: 19
Study: 24529485

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) group using LISS-DP
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 23132469

Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 150

Group type: COMPARATOR
Intervention: No catheter
Number of subjects: 150
Study: 20447070

Group type: EXPERIMENTAL
Intervention: L-T3
Number of subjects: 10

Group type: COMPARATOR
Intervention: L-T4
Number of subjects: 10
Study: 17881144

Group type: EXPERIMENTAL
Intervention: RT+HT
Number of subjects: 114

Group type: COMPARATOR
Intervention: RT
Number of subjects: 114
Study: 16331394

Group type: EXPERIMENTAL
Intervention: Neurophysiological and neuropsychological studies in idiopathic RBD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of early markers of neurodegenerative disorders in idiopathic RBD
Number of subjects: 0
Study: 14629242

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0
Study: 10591431

Group type: EXPERIMENTAL
Intervention: Gordon Diagnostic System (GDS)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 159
Study: 8913316

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) administration post-ABMT
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no GM-CSF administration)
Number of subjects: 34
Study: 1862207

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 200 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 30
Study: 6849284

Group type: EXPERIMENTAL
Intervention: Diet with 94 g protein
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diet with 65 g protein
Number of subjects: 10
Study: 30686560

Group type: EXPERIMENTAL
Intervention: Systematic GOLD‐HAS hetero‐questionnaire
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Coordination of the patient's path to facilitate access to spirometry
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Combination of the two strategies (questionnaire and coordination)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 176
Study: 30274848

Group type: EXPERIMENTAL
Intervention: Conventional consultation with additional video-assisted information (interventional group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional face-to-face consultation (conventional group)
Number of subjects: 113
Study: 26304064

Group type: EXPERIMENTAL
Intervention: Qualitative description of imprecision in risk
Number of subjects: 2663

Group type: EXPERIMENTAL
Intervention: Quantitative description of imprecision in risk
Number of subjects: 2663

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative methods
Number of subjects: 2663
Study: 24316553

Group type: EXPERIMENTAL
Intervention: GOLFIG regimen (gemcitabine 1000 mg/m² on day 1; oxaliplatin 85 mg/m² on day 2; levofolinate 100 mg/m² on days 1-2; 5-fluorouracil 400 mg/m² bolus followed by 24 h infusion at 800 mg/m² on days 1-2; GM-CSF 100 μg subcutaneously days 3-7; aldesleukin 0.5 MIU bi-daily days 8-14 and 17-30)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX chemotherapy
Number of subjects: 0
Study: 22208418

Group type: EXPERIMENTAL
Intervention: Lottery incentive condition (64% completion rate)
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Grocery gift certificate condition (44% completion rate)
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Comparison condition (40% completion rate)
Number of subjects: 1299
Study: 20113691

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (active treatment)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Tooth polishing (control)
Number of subjects: 757
Study: 17634538

Group type: EXPERIMENTAL
Intervention: Plasma TIMP-1
Number of subjects: 90
Study: 15604046

Group type: EXPERIMENTAL
Intervention: New 3-item, 5-stage measure of smoking initiation and progression
Number of subjects: 2504
Study: 12479631

Group type: EXPERIMENTAL
Intervention: Hormone/estrogen replacement therapy (HRT/ERT)
Number of subjects: 49